These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29960044)

  • 1. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.
    Gilli F; De La Torre AL; Royce DB; Pachner AR
    Int Immunopharmacol; 2018 Sep; 62():1-6. PubMed ID: 29960044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
    Khan OA; Dhib-Jalbut SS
    Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
    Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
    J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
    Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
    Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C; Gibassier J; Oger J; Le Page E; Edan G
    Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR; Warth JD; Pace A; Goelz S;
    Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
    Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
    Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
    Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
    Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.
    Libertinova J; Meluzinova E; Matoska V; Zajac M; Kovarova I; Havrdova E; Horakova D; Tomek A; Marusic P; Bojar M
    Brain Behav; 2017 Mar; 7(3):e00644. PubMed ID: 28293479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
    Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
    J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F; Schellekens H; Bertolotto A
    J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
    Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
    J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.